Efficacy of atorvastatin for achieving cholesterol targets after LDL-cholesterol based dose selection in patients with type 2 diabetes

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 13, Issue 3, 2008, Pages 183-188

  Ferrer Garcia, Juan Carlos ^a   Sanchez Ballester, Eva ^a   Albalat Galera, Raquel ^a   Berzosa Sanchez, Miguel ^a   Herrera Ballester, Agustín ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

Atorvastatin; Dyslipidemia; Low density lipoprotein cholesterol; Type 2 diabetes

Indexed keywords

ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEASIBILITY STUDIES; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PYRROLES; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 49749137908     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/1074248408321461     Document Type: Article

References (27)

1. De Vegt F., Dekker JM, Stehouver CD, Nijpels G., Bouter LM, Heine RJ Similar 9-year mortality risks and reproducibility for the World Health Organization and American Diabetes Association glucose tolerance categories: the Hoorn Study. Diabetes Care. 2000 ; 23: 40-46.
2. Stamler J., Vaccaro O., Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993 ; 16: 434-444.
3. Haffner SM: Management of dyslipidemia in adults with diabetes. Diabetes Care. 2003 ; 26 (suppl 1). 83-86.
4. Turner RC, Millns H., Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998 ; 316: 823-828.
5. American Diabetes Association. Clinical practice recommendations. Diabetes Care. 2004 ; 27: S1 - S150.
6. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Panel Treatment III) final report. Circulation. 2002 ; 106: 3143-3321.
7. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL-cholesterol by 25 to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 1995 ; 15: 678-682.
8. The Diabetes Atorvastatin Lipid Intervention (DALI) Study Group. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia. Diabetes Care. 2001 ; 24: 1335-1341.
9. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004 ; 364: 685-696.
10. Jones P., Kafonek S., Laurora I., Hunninghake D. for the CURVES Investigators. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998 ; 81: 582-587.
11. Friedwald WT, Levy RI, Frederickson DS Estimation of concentration of low density lipoprotein cholesterol in plasma without the use of preparative ultracentrifuge. Clin Chem. 1972 ; 18: 499-502.
12. Greving JP, Denig P., de Zeeuw D., Bilo HJG, Haaijer-Ruskamp FM Trends in hyperlipidemia and hypertension management in type 2 diabetes patients from 1998-2004: a longitudinal observational study. Cardiovasc Diabetol. 2007 ; 6: 25.
13. Kerr EA, Smith DM, Hogan MM, et al. Building a better quality measure: are some patients with 'poor quality' actually getting good care ? Med Care. 2003 ; 41: 1173-1182.
14. Arroyo J., Badía X., de la Calle H., et al. Management of type 2 diabetic patients in primary care in Spain. Med Clin (Barc). 2005 ; 125: 166-172.
15. Monkman D. Treating dyslipidaemia in primary care. The gap between policy and reality is large in the UK. BMJ. 2000 ; 321: 1299-1300.
16. Jones PH, McKenney JM, Karalis DG, Downey J. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. Am Heart J. 2005 ; 149: e1 - e8.
17. McPherson R., Angus C., Murray P., Genest J. Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease: the Women's Atorvastatin Trial on Cholesterol (WATCH). Am Heart J. 2001: 141 ; 949-956.
18. Aguilar-Salinas C., Gomez-Perez F., Posadas-Romero C., et al. Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label study. Atherosclerosis. 2000 ; 152: 489-496.
19. Martineau P., Gaw A., De Teresa E., et al. Effect of individualizing starting doses of statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study. Atherosclerosis. 2007 ; 191: 135-146.
20. Ducobu J., Claeys M., Commers K., et al. Efficacy of atorvastatin after LDL-cholesterol-based dose selection in high risk dyslipidaemic patients: results of the target dose study Curr Med Res Opin. 2007 ; 23: 1821-1827.
21. Newman CB, Palmer G., Silbershatz H., Szarek M. Safety of atorvastatin derived from analysis of 44 completed trials in 9416 patients. Am J Cardiol. 2003 ; 92: 670-676.
22. Garg R., Vasamreddy CR, Blumenthal RS Non-high-density lipoprotein cholesterol: why lower is better. Prev Cardiol. 2005 ; 8: 173-177.
23. Choi BG, Vilahur G., Viles-Gonzalez JF, Badimon JJ The role of high-density lipoprotein cholesterol in atherothrombosis. Mt Sinai J Med. 2006 ; 73: 690-701.
24. Chong PH, Kezele, R., Franklin C. High-density lipoprotein cholesterol and the role of statins. Circ J. 2002 ; 66: 1037-1044.
25. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003 ; 92: 152-160.
26. Sever PS, Dahlöf B., Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003 ; 361: 1149-1157.
27. Heinonen TM, Stein E., Weiss SR, et al. The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-masked study. Clin Ther. 1996 ; 18: 853-863.